@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAd-qrZSGI3_f2iSWEzSpAhMxxdFeZ0ES2AmKufASHb0s> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAd-qrZSGI3_f2iSWEzSpAhMxxdFeZ0ES2AmKufASHb0s#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 geneProductOf: mgi:103178 ;
    a Protein: .
  sub:_2 occursIn: species:10090 ;
    rdf:object go:0008219 ;
    rdf:predicate belv:decreases ;
    rdf:subject sub:_1 ;
    a rdf:Statement .
  sub:assertion rdfs:label "p(MGI:Vegfa) -| bp(GO:\"cell death\")" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_4 ;
    pav:version "1.4" .
  sub:_3 prov:value "Furthermore, with the use of a tetracycline-regulated expression system, it has been demonstrated that VEGF withdrawal can force newly formed tumor blood vessels into regression (6). Finally, in vitro studies have demonstrated that VEGF mediates this survival function for endothelial cells through VEGFR-2 and its downstream signal transduction pathways (7), suggesting that interference with VEGF/VEGFR-2 signaling may exert not only anti-angiogenic but also anti-vascular efficacy." ;
    prov:wasQuotedFrom pubmed:14657001 .
  sub:_4 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:14657001 ;
    prov:wasDerivedFrom beldoc: , sub:_3 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:30:18.858+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}